Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase.
about
Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolismRole of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovirTransition state analogue discrimination by related purine nucleoside phosphorylasesBeyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteinsPlasmodium falciparum parasites are killed by a transition state analogue of purine nucleoside phosphorylase in a primate animal modell -Enantiomers of Transition State Analogue Inhibitors Bound to Human Purine Nucleoside PhosphorylaseSlow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo ActivityA Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosisMalarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised targetSalmonella enterica MTAN at 1.36 Å Resolution: A Structure-Based Design of Tailored Transition State AnalogsInhibition and Structure of Toxoplasma gondii Purine Nucleoside PhosphorylaseEnzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimesTransition StatesThe ligand binding mechanism to purine nucleoside phosphorylase elucidated via molecular dynamics and machine learning.Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.Drug-target residence time: critical information for lead optimization.A beta-fluoroamine inhibitor of purine nucleoside phosphorylasePurine and pyrimidine pathways as targets in Plasmodium falciparum.Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimicsSlow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitorsEnzymatic transition state theory and transition state analogue design.Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.Guanosine negatively modulates the gastric motor function in mouse.Design and in silico screening of inhibitors of the cholera toxin.Energetic mapping of transition state analogue interactions with human and Plasmodium falciparum purine nucleoside phosphorylases.Structural rationale for the affinity of pico- and femtomolar transition state analogues of Escherichia coli 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase.Privileged Electrophile Sensors: A Resource for Covalent Drug Development.Drug-Target Kinetics in Drug Discovery.Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase.Erythrocytic adenosine monophosphate as an alternative purine source in Plasmodium falciparum.Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylaseTransition-state analysis of S. pneumoniae 5'-methylthioadenosine nucleosidaseImmucillins in custom catalytic-site cavities.Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.Intracellular rebinding of transition-state analogues provides extended in vivo inhibition lifetimes on human purine nucleoside phosphorylase.Genetic resistance to purine nucleoside phosphorylase inhibition in Plasmodium falciparum.An Immucillin-Based Transition-State-Analogous Inhibitor of tRNA-Guanine Transglycosylase (TGT).Link between a high for drug binding and a fast clinical action: to be or not to be?
P2860
Q24313599-E527322F-4037-4094-BF3F-34974A2B5D22Q24321512-FF96F293-E67E-44B4-B4C1-D2B4B8852005Q24643026-D67FE34D-CBE7-47E6-BC0B-4EC14E093CCBQ24649147-2EB23D4B-3B34-4667-983C-8935BBD76E74Q27314759-C5C3897D-EE5D-46DF-AB66-969A0946DFCCQ27649389-4BB9DC3A-3C5B-4AD2-B0C1-03006D848072Q27653711-E14D57F1-D597-417C-AD10-2DD07CB23D65Q27660104-AFA44647-16EA-4482-BA03-EC5FF0F37DFAQ27674154-DB13AF75-F6F3-42B2-A545-DD6C5158541FQ27678174-903C92DE-B982-4250-BA3F-1ECCCCB650CFQ27681944-F37622DA-BAE4-4285-A988-2A170F40B271Q28240827-C5E0DFBE-D079-414B-B111-3E6CD06EBFDDQ28749913-5F522C8E-50BB-4D5F-9F62-BA171B4F5C56Q30618624-1EEDE6FF-F9AD-4028-A8E8-BDA9A9A149F7Q33951142-4615126D-BC94-4E9A-8AC5-FA6071015726Q34054343-B2B9E496-EC11-4689-ADC7-603ACB1217A4Q35869783-8B7EF7E8-BA31-4190-A6C7-8D391241F582Q35870244-6A0B957E-15D1-43E6-94EB-91E6078F28C3Q36222921-FACD8650-460C-4A0C-BF2A-74D99F83AE7DQ36493862-D73918A3-AB89-427E-B5B8-1C0EED1830D6Q36906493-5EF6B5DA-18C7-40C4-B0B0-036A4625A4AFQ37231598-D1687069-32FB-4B5E-A541-B50C53C11B05Q37348966-A1616818-43D0-4C93-BDB9-B49FCCC2C574Q37468707-E0737B04-9C02-4517-8814-DE216FA22DBBQ38088362-95EA6AD7-A265-4D03-A275-D85647E7573DQ38473587-66C80374-D975-453F-B144-36FC172111F9Q38474958-E1A9561B-258F-4D74-B9C2-389382F1310CQ38710055-2A538852-1F07-44AD-B09E-04BF07BEF6BEQ39391104-E12E73CB-0952-4B22-A933-0A04B0D1185BQ40567992-D84AFD2D-D424-4F19-97F2-86629F92D253Q41817367-C59074BB-D7F9-43DC-A14A-F84A7050E905Q41835997-2BA43FB9-0B6F-4E0D-A425-4684FA5711C5Q42410823-A86345BF-8221-4CB9-84D6-76A7276FFF6AQ43143168-74CFF6F6-5D4A-4913-A4C7-971900854CE1Q46089532-7F26127F-7951-4D31-AA6E-47898A16C76FQ47971374-25B50E24-3CDA-4CC4-A410-A12E460BED8CQ50026494-F2222147-AB33-427F-BFAC-BD7D0A3DB360Q53186937-5F7D5AFD-2EB4-44C1-B060-930DC68BF6D6Q57133316-73B4BED4-525A-4946-8D24-59B2BD20E9FF
P2860
Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@en
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@nl
type
label
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@en
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@nl
prefLabel
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@en
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@nl
P2093
P2860
P356
P1476
Achieving the ultimate physiol ...... rine nucleoside phosphorylase.
@en
P2093
Andrzej Lewandowicz
Peter C Tyler
Vern L Schramm
P2860
P304
31465-31468
P356
10.1074/JBC.C300259200
P407
P577
2003-07-03T00:00:00Z